Synopsis
Synopsis
0
EU WC
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Fosfomycin
2. Fosfomycin Trometamol Salt
3. Fosfomycin Tromethamine
4. Phosphomycin
5. Phosphonomycin
6. Tromethamine, Fosfomycin
1. 78964-85-9 (tromethamine)
2. [1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]azanium;hydroxy-[(2r,3s)-3-methyloxiran-2-yl]phosphinate
3. Tromethamine-fosfomycin
4. Fosfotricin
5. Monurol Sachet
6. Fosfomycin Compd. With Trometamol
7. Einecs 279-018-8
8. Fosfomycin Tromethaminel
9. Unii-7fxw6u30gy
10. Akos015896108
11. Ac-4209
12. Ks-1266
13. (2r-cis)-(3-methyloxiranyl)phosphonic Acid, Compound With 2-amino-2-(hydroxymethyl)propane-1,3-diol (1:1)
| Molecular Weight | 259.19 g/mol |
|---|---|
| Molecular Formula | C7H18NO7P |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 4 |
| Exact Mass | 259.08208891 g/mol |
| Monoisotopic Mass | 259.08208891 g/mol |
| Topological Polar Surface Area | 161 Ų |
| Heavy Atom Count | 16 |
| Formal Charge | 0 |
| Complexity | 190 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
About the Company : Sumar Biotech LLP, registered in January 2018, is a startup approved by the Gujarat State Biotechnology Mission. Founded by young entrepreneurs and experienced research and manufac...
Octavius Pharma has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
About the Company : Octavius Pharma is a global leader in Directly Compressible Granules with over 45 years of experience in formulation development, manufacturing, and commercialization. Its portfoli...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing APIs, including hard-to-find drug substances, for pharmaceutical and biotech industries. LGM also operates as a full-service drug product ...
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...
Bioquim: An European GMP-certified company manufacturing bulk APIs, specializing in sterile lyophilization and chemical synthesis.
About the Company : Bioquim is a European company specializing in bulk oral and sterile APIs for the pharmaceutical industry. With over 40 years of experience, the company supplies corticosteroids, pe...
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
About the Company : Honour is a leading global CDMO and trusted manufacturer of specialty chemicals and ingredients, with seven world-class facilities meeting global safety and quality standards. Thro...
About the Company : Shamrock Pharmachemi Pvt Ltd. is a globally recognized API leader with 26+ years in human and veterinary pharmaceuticals. Operating in 40+ countries, it owns two Gujarat facilities...
About the Company : Bajaj Healthcare Ltd. is a company established in 1993, services various Pharmaceuticals, Nutraceutical and Food industries globally with a spirit of scrupulousness. Bajaj Healt...

About the Company : Northeast Pharmaceutical Group Co., Ltd ( NEPG ) is a large-scale comprehensive pharmaceutical enterprise in China.It is composed of three major business segments, i.e. 1. chemical...

About the Company : Scimplify is a science-first company specializing in end-to-end development and manufacturing of specialty chemicals. We support the entire product life cycle, from contract resear...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Fosfomycin, an antibiotic, targets UDP-N-acetylglucosamine 1-carboxyvinyltransferase, showing promise in treating complicated urinary tract infections (cUTI).
Lead Product(s): Fosfomycin Trometamol,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Contepo
Study Phase: Approved FDFProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 04, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Fosfomycin Trometamol,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Meitheal Pharmaceuticals Gets FDA Approval for CONTEPO™ in Patients with cUTI, Including AP
Details : Fosfomycin, an antibiotic, targets UDP-N-acetylglucosamine 1-carboxyvinyltransferase, showing promise in treating complicated urinary tract infections (cUTI).
Product Name : Contepo
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 04, 2025

Details:
Uroxin is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Urinary Tract Infections.
Lead Product(s): Uroxin,Fosfomycin Trometamol
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Undisclosed
Sponsor: pharmaSuisse
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 26, 2024

Lead Product(s) : Uroxin,Fosfomycin Trometamol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : pharmaSuisse
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of Collagen, Propolis Plus Quercetin (Proqutin®), Bacillus Coagulans, Hyaluronic Acid ...
Details : Uroxin is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Urinary Tract Infections.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 26, 2024

Details:
Fosfomycin is a Antibiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Cystitis.
Lead Product(s): Fosfomycin Trometamol,Inapplicable
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Antibiotic
Sponsor: Petrovax
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 14, 2023

Lead Product(s) : Fosfomycin Trometamol,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Petrovax
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Uronext® in Women With Cystitis
Details : Fosfomycin is a Antibiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Cystitis.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 14, 2023

Details:
Fosfomycin is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Urinary Tract Infections.
Lead Product(s): Fosfomycin Trometamol,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibiotic
Sponsor: ZonMw | Saltro
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 24, 2022

Lead Product(s) : Fosfomycin Trometamol,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : ZonMw | Saltro
Deal Size : Inapplicable
Deal Type : Inapplicable
EXtended Use of FOsfomycin for the Treatment of CYstitis in Primary Care
Details : Fosfomycin is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Urinary Tract Infections.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
February 24, 2022

Details:
Fosfomycin trometamol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Urinary Tract Infections.
Lead Product(s): Fosfomycin Trometamol,Nitrofurantoin,Pivmecillinam Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Balearic Islands Health Service | Instituto de Investigación Sanitaria Aragón | Gerencia de Atención Primaria, Madrid
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 13, 2021

Lead Product(s) : Fosfomycin Trometamol,Nitrofurantoin,Pivmecillinam Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Balearic Islands Health Service | Instituto de Investigación Sanitaria Aragón | Gerencia de Atención Primaria, Madrid
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Fosfomycin trometamol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Urinary Tract Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 13, 2021

Details:
Fosfomycin Tromethamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Urinary Tract Infections.
Lead Product(s): Fosfomycin Trometamol,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Laboratorios Senosiain
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 24, 2019

Lead Product(s) : Fosfomycin Trometamol,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Laboratorios Senosiain
Deal Size : Inapplicable
Deal Type : Inapplicable
Antimicrobial Prophylaxis in Patients Who Underwent a Transurethral Resection of Bladder (TURB)
Details : Fosfomycin Tromethamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Urinary Tract Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 24, 2019

Details:
Ciprofloxacin is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Infections.
Lead Product(s): Ciprofloxacin,Trimethoprim,Sulfamethoxazole,Fosfomycin Trometamol,Pivmecillinam Hydrochloride,Amoxicillin Trihydrate,Clavulanate Acid
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Antibiotic
Sponsor: ZonMw
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 24, 2017

Lead Product(s) : Ciprofloxacin, Trimethoprim, Sulfamethoxazole, Fosfomycin Trometamol, Pivmecillinam Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : ZonMw
Deal Size : Inapplicable
Deal Type : Inapplicable
Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy.
Details : Ciprofloxacin is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Infections.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 24, 2017

Details:
Amikacin is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Amikacin,Fosfomycin Trometamol
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 16, 2016

Lead Product(s) : Amikacin,Fosfomycin Trometamol
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Open-Label Phase 1 Study of Aerosolized Amikacin and Fosfomycin in Healthy Volunteers
Details : Amikacin is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 16, 2016

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Centaurium Erythraea is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Urinary Tract Infections.
Lead Product(s): Centaurium Erythraea,Levisticum Officinale,Rosmarinus Officinalis,Fosfomycin Trometamol
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Plant Extract/Herbal
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 24, 2015

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Centaurium Erythraea,Levisticum Officinale,Rosmarinus Officinalis,Fosfomycin Trometamol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of CLR Compared to Fosfomycin Trometamol in Acute Lower uUTIs
Details : Centaurium Erythraea is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Urinary Tract Infections.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
December 24, 2015

Details:
Amikacin is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pneumonia, Bacterial.
Lead Product(s): Amikacin,Fosfomycin Trometamol
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibiotic
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 18, 2014

Lead Product(s) : Amikacin,Fosfomycin Trometamol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Amikacin is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pneumonia, Bacterial.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
August 18, 2014

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Italy
Brand Name : Ffomicina
Dosage Form : Fosfomycin 3.000Mg 2 Units
Dosage Strength : for OS 2 bust 3 g
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Towa International works to research, develop, manufacture, and market, generic and value-added medicines to patients around the world.
Regulatory Info :
Registration Country : Italy
Brand Name : PHOSFOMICIN THINK
Dosage Form : Granules For Oral Solution
Dosage Strength : 3 g
Packaging : 2 UNITS 3000 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Towa International works to research, develop, manufacture, and market, generic and value-added medicines to patients around the world.
Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Fosfomicina Pensa
Dosage Form : Granule For Oral Solution
Dosage Strength : 3G
Packaging :
Approval Date : 15-04-2012
Application Number : 75775
Regulatory Info : Authorized
Registration Country : Spain
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Fosfomicina Kern Pharma
Dosage Form : Granule For Oral Solution
Dosage Strength : 3G
Packaging :
Approval Date : 20-03-2012
Application Number : 75651
Regulatory Info : Authorized
Registration Country : Spain

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Cancelled
Registration Country : Spain
Brand Name : Fosfomicina Labiana
Dosage Form : Granule For Oral Solution In Sachet
Dosage Strength : 2G
Packaging :
Approval Date : 13-07-2016
Application Number : 81061
Regulatory Info : Cancelled
Registration Country : Spain

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Fosfomycin Qualigen
Dosage Form : Granule For Oral Solution
Dosage Strength : 3G
Packaging :
Approval Date : 13-10-2010
Application Number : 72847
Regulatory Info : Authorized
Registration Country : Spain

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Italy
Brand Name : LOWER
Dosage Form : Granules For Oral Solution
Dosage Strength : 3 g
Packaging : 2 UNITS 3000 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Italy
Brand Name : #VALUE!
Dosage Form : Fosfomycin 3.000Mg 2 Units' Oral Use
Dosage Strength : AD os groun 2 bust 3 g
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Italy
Brand Name : Ffomicina
Dosage Form : Fosfomycin 3.000Mg 2 Units' Oral Use
Dosage Strength : AD os grat 2 bust 3 g
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy

Regulatory Info :
Registration Country : Italy
Brand Name : Urof
Dosage Form : Fosfomycin 3.000Mg 2 Units' Oral Use
Dosage Strength : for OS 2 bust 3 g
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
93
PharmaCompass offers a list of Fosfomycin Trometamol API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Fosfomycin Trometamol manufacturer or Fosfomycin Trometamol supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Fosfomycin Trometamol manufacturer or Fosfomycin Trometamol supplier.
A MONUROL manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of MONUROL, including repackagers and relabelers. The FDA regulates MONUROL manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. MONUROL API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of MONUROL manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A MONUROL supplier is an individual or a company that provides MONUROL active pharmaceutical ingredient (API) or MONUROL finished formulations upon request. The MONUROL suppliers may include MONUROL API manufacturers, exporters, distributors and traders.
click here to find a list of MONUROL suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A MONUROL DMF (Drug Master File) is a document detailing the whole manufacturing process of MONUROL active pharmaceutical ingredient (API) in detail. Different forms of MONUROL DMFs exist exist since differing nations have different regulations, such as MONUROL USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A MONUROL DMF submitted to regulatory agencies in the US is known as a USDMF. MONUROL USDMF includes data on MONUROL's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The MONUROL USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of MONUROL suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The MONUROL Drug Master File in Japan (MONUROL JDMF) empowers MONUROL API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the MONUROL JDMF during the approval evaluation for pharmaceutical products. At the time of MONUROL JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of MONUROL suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a MONUROL Drug Master File in Korea (MONUROL KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of MONUROL. The MFDS reviews the MONUROL KDMF as part of the drug registration process and uses the information provided in the MONUROL KDMF to evaluate the safety and efficacy of the drug.
After submitting a MONUROL KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their MONUROL API can apply through the Korea Drug Master File (KDMF).
click here to find a list of MONUROL suppliers with KDMF on PharmaCompass.
A MONUROL CEP of the European Pharmacopoeia monograph is often referred to as a MONUROL Certificate of Suitability (COS). The purpose of a MONUROL CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of MONUROL EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of MONUROL to their clients by showing that a MONUROL CEP has been issued for it. The manufacturer submits a MONUROL CEP (COS) as part of the market authorization procedure, and it takes on the role of a MONUROL CEP holder for the record. Additionally, the data presented in the MONUROL CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the MONUROL DMF.
A MONUROL CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. MONUROL CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of MONUROL suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing MONUROL as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for MONUROL API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture MONUROL as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain MONUROL and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a MONUROL NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of MONUROL suppliers with NDC on PharmaCompass.
MONUROL Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of MONUROL GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right MONUROL GMP manufacturer or MONUROL GMP API supplier for your needs.
A MONUROL CoA (Certificate of Analysis) is a formal document that attests to MONUROL's compliance with MONUROL specifications and serves as a tool for batch-level quality control.
MONUROL CoA mostly includes findings from lab analyses of a specific batch. For each MONUROL CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
MONUROL may be tested according to a variety of international standards, such as European Pharmacopoeia (MONUROL EP), MONUROL JP (Japanese Pharmacopeia) and the US Pharmacopoeia (MONUROL USP).